Search by Bookstore
Holdings of Libraries in Japan
This page shows libraries in Japan other than the National Diet Library that hold the material.
Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.
Search by Bookstore
Bibliographic Record
You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.
- Material Type
- 文書・図像類
- Author/Editor
- 永井, 拓
- Author Heading
- Publication, Distribution, etc.
- Alternative Title
- Characterization and targeting Folate receptor-beta expressed tumor associated macrophages in glioblastoma
- Text Language Code
- jpn
- Target Audience
- 一般
- Note (General)
- 2011-2013年度科学研究費助成事業（基盤研究（C））研究成果報告書 課題番号：23592134 研究代表者：永井拓（鹿児島大学・医歯（薬）学総合研究科・講師）マクロファージは局在する組織で多様化する特徴を持つ。腫瘍組織では増殖や転移、腫瘍免疫回避に働くと考えられている。これまでに葉酸受容体β（FRβ）は、悪性度の高い脳腫瘍に局在するマクロファージで高発現する事を報告してきた。本研究では、抗がん免疫（ワクチン等）が生じ難い動物モデル（F98細胞移植ラットモデル）に抗FRβ抗体トキシンを投与し、FRβマクロファージ除去によるワクチン増強効果を検討した。その結果、抗体トキシンによる免疫原性はワクチン効果の減弱化に関与する可能性が示唆された。この問題を解決するために新たに抗体トキシンを設計・作製し、動物モデルで有効性（免疫原性）の検討を行った。Folate receptor-beta (FRb) is over expressed in tissue-activated macrophages in autoimmune diseases and some tumors (e.g. glioblastoma). We previously determined that FRb-macrophages in glioma may play a role to promote tumor growth. The present study evaluated the efficacy of targeting of FRb-macrophages by anti-FRb immunotoxin for treating immunotherapy of weakly immunogenic F98 glioma rat models. Fischer rats received an intracerebral implantation of F98 cells. After 3 days, subcutaneous administration of vaccination (freeze/thaw treated F98) were performed in presence/absence of immunotoxin (intraperitoneal administration). However, no significant differences in survival times were observed. When combined liveing cell F98 and immunotoxin administration enhanced survival times, but significance was not observed. We investigated the presence of anti-immunotoxin antibodies. We further developed newly immunotoxin which showed low immunogenicity and used for long-term administration.